This classification was primarily based on the analyses of The Cancer Genome Atlas (TCGA) data, which predominantly included low- to intermediate-risk DTC cases associated with a low tumor mutation burden (TMB) and low PD-L1 expression [18,19]. The gene discussed is CD274; the disease is neoplasm.